The chair of the US FDA’s Endocrinologic & Metabolic Drugs Advisory Committee offered an especially apt summary of the panel’s Oct. 24-25 discussion of elements of FDA’s safety standards for diabetes drugs: "Everybody said they were saying the same thing, but you all said something different."
The chair, Emory University’s Peter Wilson, was attempting to summarize the specific points made in response to a question about...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?